Delivery Order SPE2DB25D3007-SPE2DB25FWSRM
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of NovoLog 100 Unit/mL vials in 10mL quantities, with a ceiling value of $2,955.82. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by September 9, 2025. The delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $4,819.02 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL). The contract, classified as a firm fixed price delivery order with an ultimate completion date of August 18, 2025, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation. This delivery order is issued...
- The Defense Logistics Agency awarded a $2,737.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of NovoLog 100 Unit/mL vials (10mL). The contract, which is a child order under a larger indefinite delivery contract, carries an ultimate completion date of August 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a non-competitive, competitively awarded transaction...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of NovoLog 100 unit/mL vials (10 mL) with a ceiling value of $3,162.88. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The order is due for completion by July 30, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin used in diabetes...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $1,424.55. This competitive award, issued under a firm fixed-price delivery order contract type, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The order does not utilize a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of NovoLog 100 Unit/mL vials (10mL) with a ceiling value of $1,243.75. This is a firm fixed price delivery order with no set-aside designation, executed as a competitive award through the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $3,648.07. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 24, 2025. This delivery order falls under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) with a ceiling value of $1,296.60 under a firm fixed-price contract. The award was made on August 22, 2025, with an ultimate completion date of August 25, 2025. This contract represents a non-set-aside, competitively awarded delivery order supporting the federal government's pharmaceutical supply chain. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $1,248.90 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL). This is a firm fixed price delivery order with no set-aside designation, utilizing competitive procurement procedures. The order is scheduled for completion by July 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin product...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of NovoLog 100 Unit/ML vial 10ML insulin medication. This is a firm fixed-price delivery order with a ceiling value of $7,929.22 and an ultimate completion date of August 28, 2025. The contract is not set-aside and was competitively awarded. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, reflecting the...
- SPE2DB25D3007Indefinite Delivery Contract
- SPE2DB25D3007-SPE2DB25FWSRMDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL units) with a ceiling value of $2,240.56. This firm fixed-price delivery order is scheduled for completion by August 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting the company's competitive capability in federal pharmaceutical procurement. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the supply of medications, vaccines, and medical supplies to support military healthcare programs worldwide. NovoLog, a rapid-acting insulin product, represents a critical pharmaceutical commodity within the Defense Health Agency's medical supply requirements, and this order exemplifies the routine delivery orders executed against the broader framework agreement to fulfill ongoing military medical needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 8/22/25 |